All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the #ASCO22 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)?
What is on the horizon for the frontline treatment of MCL?
Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in the relapsed/refractory setting; results of studies, such as SHINE, have explored this. Finally, Kumar discusses other therapeutic options and outlines adverse events and efficacy seen in the current OASIS phase III trial.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Efficacy and safety of ibrutinib + BR in the treatment of elderly patients with MCL: Primary analysis from SHINE III
The primary analysis of the ongoing phase III SHINE trial shows that ibrutinib + BR significantly improved PFS in elderly patients...
Results from the OAsis phase I/II trial on ibrutinib, venetoclax plus obinutuzumab in patients with newly diagnosed mantle cell lymphoma
During the 2020 European Hematology Association (EHA) Annual Congress, Steven Le Gouill presented data from...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox